Michael A Sugarman1, Irving Kirsch2, Jonathan D Huppert3. 1. Department of Psychology, Bedford Veterans Affairs Medical Center, United States. Electronic address: Mike.Sugarman@wayne.edu. 2. Harvard Medical School, United States. 3. Department of Psychology, The Hebrew University of Jerusalem, Israel.
Abstract
BACKGROUND: Previous studies have indicated that obsessive-compulsive disorder (OCD) might have a reduced placebo response compared to other anxiety-related disorders including generalized anxiety disorder, panic disorder, post-traumatic stress disorder, and social anxiety disorder. No previous analysis has directly compared antidepressant and placebo responses between OCD and these conditions. METHOD: We analyzed pre-post change scores within drug and placebo groups as well as between-groups change scores (i.e., drug compared to placebo) for all FDA-approved antidepressants for the treatment of these five anxiety-related disorders. Antidepressants included duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine. Random effects meta-analysis was used to examine all trials submitted to the FDA, plus additional post-approval trials available from manufacturer-sponsored clinical trial registers. Clinician-rated symptom inventories were the outcome measures for all conditions to facilitate comparisons across diagnoses. RESULTS: Fifty-six trials met inclusion criteria. OCD had significantly lower pre-post effect sizes (ps<0.003) for both placebo (Hedges' g=0.49) and antidepressants (g=0.84) compared to the other four conditions (gs between 0.70 and 1.10 for placebo and 1.11 and 1.40 for antidepressants). However, the drug-placebo effect sizes did not significantly differ across diagnoses (Q(4)=6.09, p=0.193, I2 =34.3% [95% CI: -7.0,59.7]), with gs between=0.26 and 0.39. CONCLUSIONS: Overall pre-post change scores were smaller for OCD compared to other anxiety disorders for both antidepressants and placebo, although drug-placebo effects sizes did not significantly differ across disorders. Theoretical and clinical implications for the understanding and treatment of OCD are discussed. Published by Elsevier B.V.
BACKGROUND: Previous studies have indicated that obsessive-compulsive disorder (OCD) might have a reduced placebo response compared to other anxiety-related disorders including generalized anxiety disorder, panic disorder, post-traumatic stress disorder, and social anxiety disorder. No previous analysis has directly compared antidepressant and placebo responses between OCD and these conditions. METHOD: We analyzed pre-post change scores within drug and placebo groups as well as between-groups change scores (i.e., drug compared to placebo) for all FDA-approved antidepressants for the treatment of these five anxiety-related disorders. Antidepressants included duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine. Random effects meta-analysis was used to examine all trials submitted to the FDA, plus additional post-approval trials available from manufacturer-sponsored clinical trial registers. Clinician-rated symptom inventories were the outcome measures for all conditions to facilitate comparisons across diagnoses. RESULTS: Fifty-six trials met inclusion criteria. OCD had significantly lower pre-post effect sizes (ps<0.003) for both placebo (Hedges' g=0.49) and antidepressants (g=0.84) compared to the other four conditions (gs between 0.70 and 1.10 for placebo and 1.11 and 1.40 for antidepressants). However, the drug-placebo effect sizes did not significantly differ across diagnoses (Q(4)=6.09, p=0.193, I2 =34.3% [95% CI: -7.0,59.7]), with gs between=0.26 and 0.39. CONCLUSIONS: Overall pre-post change scores were smaller for OCD compared to other anxiety disorders for both antidepressants and placebo, although drug-placebo effects sizes did not significantly differ across disorders. Theoretical and clinical implications for the understanding and treatment of OCD are discussed. Published by Elsevier B.V.
Authors: Cosima Locher; Helen Koechlin; Sean R Zion; Christoph Werner; Daniel S Pine; Irving Kirsch; Ronald C Kessler; Joe Kossowsky Journal: JAMA Psychiatry Date: 2017-10-01 Impact factor: 21.596
Authors: Joseph K Carpenter; Leigh A Andrews; Sara M Witcraft; Mark B Powers; Jasper A J Smits; Stefan G Hofmann Journal: Depress Anxiety Date: 2018-02-16 Impact factor: 6.505
Authors: D Bennabi; A Yrondi; T Charpeaud; J-B Genty; S Destouches; S Lancrenon; N Allaili; F Bellivier; T Bougerol; V Camus; O Doumy; J-M Dorey; F Haesebaert; J Holtzmann; C Lançon; M Lefebvre; F Moliere; I Nieto; C Rabu; R Richieri; L Schmitt; F Stephan; G Vaiva; M Walter; M Leboyer; W El-Hage; B Aouizerate; E Haffen; P-M Llorca; P Courtet Journal: BMC Psychiatry Date: 2019-01-30 Impact factor: 3.630